Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. Fundamental Analysis
Shin Nippon Biomedical Laboratories, Ltd. (2395.T) shows moderate financial fundamentals with a PE ratio of 14.75, profit margin of 12.72%, and ROE of 9.60%. The company generates $31.4B in annual revenue with strong year-over-year growth of 22.55%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2395.T's fundamental strength across five key dimensions:
Efficiency Score
Weak2395.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent2395.T trades at attractive valuation levels.
Growth Score
Moderate2395.T shows steady but slowing expansion.
Financial Health Score
Excellent2395.T maintains a strong and stable balance sheet.
Profitability Score
Weak2395.T struggles to sustain strong margins.
Key Financial Metrics
Is 2395.T Expensive or Cheap?
P/E Ratio
2395.T trades at 14.75 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2395.T's PEG of -1.03 indicates potential undervaluation.
Price to Book
The market values Shin Nippon Biomedical Laboratories, Ltd. at 1.11 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.12 times EBITDA. This is generally considered low.
How Well Does 2395.T Make Money?
Net Profit Margin
For every $100 in sales, Shin Nippon Biomedical Laboratories, Ltd. keeps $12.72 as profit after all expenses.
Operating Margin
Core operations generate 6.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.60 in profit for every $100 of shareholder equity.
ROA
Shin Nippon Biomedical Laboratories, Ltd. generates $3.53 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shin Nippon Biomedical Laboratories, Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Shin Nippon Biomedical Laboratories, Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
2395.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.75
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.11
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.79
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.08
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 2395.T Stacks Against Its Sector Peers
| Metric | 2395.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.75 | 27.91 | Better (Cheaper) |
| ROE | 9.60% | 687.00% | Weak |
| Net Margin | 12.72% | -45285.00% (disorted) | Strong |
| Debt/Equity | 0.79 | 0.33 | Weak (High Leverage) |
| Current Ratio | 1.08 | 2795.76 | Neutral |
| ROA | 3.53% | -13557.00% (disorted) | Weak |
2395.T outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shin Nippon Biomedical Laboratories, Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
122.61%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
93.10%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
133.09%
Industry Style: Defensive, Growth, Innovation
High Growth